News headlines about Novartis AG (NYSE:NVS) have been trending somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis AG earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.0378691454564 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Novartis Vision Drug Shows Positive Results in Phase 3 Trials (ih.advfn.com)
- Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial (finanznachrichten.de)
- Novartis launches heart drug counter-offensive (finance.yahoo.com)
- Novartis posts eye drug data amid play for Eylea’s turf (finance.yahoo.com)
- Better Buy: Exelixis, Inc. vs. Novartis AG (finance.yahoo.com)
Shares of Novartis AG (NYSE:NVS) opened at $82.86 on Tuesday. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The company has a market cap of $194,877.70, a P/E ratio of 17.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.72.
Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. Novartis AG had a net margin of 13.73% and a return on equity of 15.77%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the firm posted $1.23 EPS. equities research analysts anticipate that Novartis AG will post 4.75 earnings per share for the current year.
Several equities research analysts recently weighed in on NVS shares. Zacks Investment Research raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research note on Tuesday, September 19th. BidaskClub raised shares of Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Cowen and Company set a $90.00 target price on shares of Novartis AG and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Leerink Swann upped their target price on shares of Novartis AG from $89.00 to $91.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the stock. Novartis AG presently has an average rating of “Hold” and a consensus price target of $85.32.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.